All In Biotech

Drug Trial Radar · NCT07573449

How [14C]-JNT-517 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Male Participants

A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]JNT-517 Following a Single Oral Dose in Healthy Male Participants

Last checked: Nov 19, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Jan 22, 2024

Primary completion

Jan 22, 2025

Study completion Feb 27, 2025

Sponsor

Sponsor type
Industry
First posted
May 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the absorption, metabolism and excretion of \[14C\]-JNT-517 and to characterize and determine the metabolites present in plasma, urine, and feces in healthy male participants following a single oral administration.

Conditions

  • Healthy Volunteers

Interventions

  • [14C]-JNT-517Drug

    Suspension

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Radioactivity Recovery (fet1-t2) in Urine and FecesTime frame: Up to Day 9
  2. Relative Amounts Of Radioactivity Excreted in Urine and FecesTime frame: Up to Day 9
  3. Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-∞) of [14C]-JNT-517 And Its Metabolites in PlasmaTime frame: Up to Day 9
  4. Area Under The Concentration-Time Curve From Time Zero to The Time Of The Last Quantifiable Concentration (AUC0-tlast) of [14C]-JNT-517 And Its Metabolites in PlasmaTime frame: Up to Day 9
  5. Maximum Plasma Concentration (Cmax) of [14C]-JNT-517 And Its Metabolites in PlasmaTime frame: Up to Day 9
  6. Time to Reach Maximum (Peak) Observed Plasma Concentration (Tmax) of [14C]-JNT-517 And Its Metabolites in PlasmaTime frame: Up to Day 9
  7. Apparent Terminal Elimination Half-Life (t½) of [14C]-JNT-517 And Its Metabolites in PlasmaTime frame: Up to Day 9
  8. AUC₀-∞ of Total Radioactivity in Plasma And Whole BloodTime frame: Up to Day 9
  9. AUC₀-tlast of Total Radioactivity in Plasma And Whole BloodTime frame: Up to Day 9
  10. Cmax of Total Radioactivity in Plasma and Whole BloodTime frame: Up to Day 9
  11. Tmax of Total Radioactivity in Plasma and Whole BloodTime frame: Up to Day 9
  12. t½ of Total Radioactivity in Plasma and Whole BloodTime frame: Up to Day 9

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fortrea Clinical Research Unit Inc.

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.